ClinicalTrials.gg
RecruitingNCT06440317PLAQSIRISUpdated Nov 2, 2026

Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane

An observational study in Sepsis, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University Hospital, Bordeaux · Observational

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 2, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Sepsis with a site in France — 41 open to participants now, 46 under way, 5 of them phase 3. Sepsis · France.

Planned enrollment
84th of 97
30 · median 170
Started
2026
with 19 others
Observational
97 of 209
20 open now
Primary completion
2027-10
later than 29 of 45 live
Registered
172nd of 209
by date

Among the 209 studies in Sepsis with a site in France, this one is the 84th largest by planned enrollment of the 97 observational ones that give a count, is one of 20 that started in 2026, is one of 97 observational ones, reaches primary completion later than 29 of the 45 other live ones, and was the 172nd registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

41 of the 209 studies in Sepsis with a site in France are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Sepsis with a site in France, or all of them as a file.
02

Study summary

Sepsis remains a global scourge. Before the SARS-CoV-2 pandemic, the World Health Organization estimated approximately 49 million cases annually, resulting in 11 million deaths. Defined by dysregulated host response to infection, sepsis leads to vital organ failure. Renal dysfunction affects about half of ICU patients, necessitating extracorporeal renal replacement therapy in approximately 10% of cases, alongside coagulation system involvement typified by thrombocytopenia. Immunothrombotic phenomena are pivotal in sepsis pathophysiology, activating coagulation and disrupting immune responses. Microcirculatory impairment, mediated by neutrophils, monocytes, and platelets, worsens vital organ perfusion. Excessive production of Neutrophil Extracellular Traps (NETs) is implicated in microcirculatory compromise during sepsis.

03

Conditions studied

  • Sepsis

Browse trials for

Keywords

  • Intensive Care
  • Immunothrombosis
  • NETs
  • Neutrophils
  • Platelets
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Eligible patients for this study will undergo renal replacement therapy using two hemofiltration membranes commonly used in intensive care units

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years and older
  • Admitted to the intensive care unit with septic shock, defined as an increase in the Sequential Organ Failure Assessment (SOFA) score of at least 2 points due to infection, requiring vasopressor drugs to maintain a mean arterial pressure (MAP) ≥ 65 mmHg, and a lactate level > 2 mmol/L (18 mg/dL) despite adequate fluid resuscitation
  • Requiring renal replacement therapy according to consensus indications:

    • KDIGO stage 3 acute kidney injury with oliguria or anuria persisting for more than 72 hours
    • Urea > 40 mmol/L
    • Plasma potassium > 5.5 mmol/L despite medical treatment
    • pH \< 7.15 (pure metabolic acidosis with PaCO2 \< 30 mmHg or mixed acidosis with PaCO2 > 50 mmHg without the possibility of improving alveolar ventilation)
    • Acute pulmonary edema secondary to hydrosaline overload resulting in severe hypoxemia (oxygen flow > 5 L/min or FiO2 > 50% during mechanical ventilation to maintain SaO2 > 95%) despite diuretic therapy
  • Receiving continuous renal replacement therapy with a high-adsorption membrane (oXiris membrane) or a conventional membrane (HF1400 membrane)

Exclusion criteria

Exclusion Criteria:

  • Known history of constitutional thrombopathy (Bernard Soulier disease, Glanzmann thrombasthenia, Gray's syndrome or dense granule disease)
  • Myelodysplastic or myeloproliferative syndrome
  • thrombocytopenic purpura
  • Acute leukemia
  • Hemorrhagic shock
  • transfusion within 7 days prior to inclusion
  • Antiplatelet therapy with clopidogrel or ticagrelor within 5 days prior to inclusion, prasugrel or dipyridamole within 7 days prior to inclusion
  • Active infection or or C
  • Pregnant woman
  • Not affiliated to a social security system or not benefiting from such a system
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Hemofiltration membranes (the oXiris® membrane and the HF1400 ® membrane)

    Eligible patients for this study will undergo renal replacement therapy using two hemofiltration membranes commonly used in intensive care units.

    Device: Hemofiltration membranes (the oXiris membrane® and the HF1400® membrane)

Interventions

  • DeviceHemofiltration membranes (the oXiris membrane® and the HF1400® membrane)

    The PRISMAFLEX® or PRISMAX® control unit (pre- and post-dilution with a prescribed treatment dose \> 25 ml/kg/h) with regional citrate anticoagulation and a substitution solution by PHOXILLUM will be used regardless of the type of membrane used (the oXiris membrane and the HF 1400 membrane), also as part of routine care provided in the ICU.

06

What researchers measure

Primary outcomes

  1. Immunothrombosis : Concentration of platelet activation markers

    Dosages of platelet activation markers, before and after the renal replacement therapy membrane : oXiris membrane or conventional membrane

    Time frame: 12 months after inclusion day

Secondary outcomes

  1. NETosis : Concentration of Neutrophil Extracellular Traps

    Dosages of Neutrophil Extracellular Traps, before and after the renal replacement therapy membrane : oXiris membrane or conventional membrane

    Time frame: 12 months after inclusion day

  2. Monocyte activation : Concentration of monocyte (CD14+)

    Dosages of monocyte (CD14+), before and after the renal replacement therapy membrane : oXiris membrane or conventional membrane

    Time frame: 12 months after inclusion day

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 12 months is below that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Apr 2026 → Oct 2026, primary completion Apr 2027 → Oct 2027 and completion May 2027 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
Jun 3, 2024
StartActual
Oct 22, 2026was Apr 2026
Primary completionEst.
Oct 2027was Apr 2027
CompletionEst.
Nov 2027was May 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 2026→Oct 22, 2026 (actual)
Nov 2, 2026
Primary completion
Apr 2027→Oct 2027
Nov 2, 2026
Study completion
May 2027→Nov 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Apr 2026→Oct 22, 2026 (now actual)
    Primary completion Apr 2027→Oct 2027
    Study completion May 2027→Nov 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06440317
Responsible party
Sponsor
First posted
Jun 3, 2024
Start date
Oct 22, 2026
Primary completion
Oct 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Antoine DEWITTE, Dr
Contact
antoine.dewitte@u-bordeaux.fr
05 57 65 68 66 ext. +33
Sarah CRONIER
Contact
sara.cronier@chu-bordeaux.fr
05 57 65 68 66 ext. +33
Maria MAMANI, Pr
study chair · ImmunoConcEpT, Bordeaux University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion